NeoStem Inc  

(Public, NASDAQ:NBS)   Watch this stock  
Find more results for NBS
-0.03 (-0.58%)
After Hours: 5.01 -0.15 (-2.91%)
Oct 30, 7:28PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.02 - 5.19
52 week 4.56 - 8.29
Open 5.15
Vol / Avg. 0.00/172,437.00
Mkt cap 183.28M
P/E     -
Div/yield     -
EPS -1.76
Shares 35.31M
Beta 1.10
Inst. own 19%
Nov 4, 2014
NeoStem Inc at EBD Group BIO-Europe Conference - 5:15AM EST - Add to calendar
Oct 8, 2014
NeoStem Inc at BIO Investor Forum
Sep 26, 2014
NeoStem Inc at BioCentury Publications NewsMakers in the Biotech Industry
Sep 9, 2014
NeoStem Inc at Rodman & Renshaw Global Investment Conference
Aug 7, 2014
Q2 2014 NeoStem Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -284.47% -269.19%
Operating margin -276.91% -250.94%
EBITD margin - -239.99%
Return on average assets -46.61% -54.76%
Return on average equity -73.44% -81.45%
Employees 108 -
CDP Score - -


NEW YORK, NY 10170
United States - Map
+1-212-5844171 (Phone)
+1-646-5147787 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NeoStem, Inc. operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�s business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�s wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates. In May 2014, the Company acquired California Stem Cell, Inc.

Officers and directors

Robin L. Smith M.D. Chairman of the Board, Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Robert IV Dickey IV Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Robert A. Preti Ph.D. President and Chief Scientific Officer - PCT
Age: 57
Bio & Compensation  - Reuters
Stephen W. Potter Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Joseph Talamo Vice President, Chief Accounting Officer, Corporate Controller
Age: 45
Bio & Compensation  - Reuters
Catherine M. Vaczy Esq Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
David Schloss Vice President, Director of Human Resources
Age: 55
Bio & Compensation  - Reuters
David Altarac Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Andrew L. Pecora M.D. Chief Visionary Officer, Director
Age: 57
Bio & Compensation  - Reuters
Douglas W. Losordo M.D. Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters